About Neumora
Neumora is a company based in Watertown (United States) founded in 2020 by Robert Nelsen, Kristina Burow, Carol Suh, Paul Berns, and Mike Poole. Neumora has raised $612 million across 2 funding rounds from investors including Amgen, ARE and Citadel. The company has 110 employees as of December 31, 2024. Neumora offers products and services including Precision Toolbox and Drug Pipeline Programs. Neumora operates in a competitive market with competitors including Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
- Headquarter Watertown, United States
- Employees 110 as on 31 Dec, 2024
- Founders Robert Nelsen, Kristina Burow, Carol Suh, Paul Berns, Mike Poole
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Neumora Therapeutics, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$243.79 M (USD)-3.33as on Dec 31, 2024
-
EBITDA
-$262.83 M (USD)-40.16as on Dec 31, 2024
-
Total Equity Funding
$612 M (USD)
in 2 rounds
-
Latest Funding Round
$112 M (USD), Series B
Oct 11, 2022
-
Investors
Amgen
& 16 more
-
Employee Count
110
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Neumora
Neumora is a publicly listed company on the NASDAQ with ticker symbol NMRA in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Neumora
Neumora offers a comprehensive portfolio of products and services, including Precision Toolbox and Drug Pipeline Programs.
Integrates tools for precision medicine in CNS diseases.
Pursues novel mechanisms for brain disease treatments.
People of Neumora
Unlock access to complete
Unlock access to complete
Leadership Team
15 people
Scientific Team
11 people
Software Development Team
9 people
Senior Team
4 people
Human Resources and Administration
4 people
Product Management Team
4 people
Operations Team
3 people
Legal and Compliance
2 people
Unlock access to complete
Funding Insights of Neumora
Neumora has successfully raised a total of $612M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $112 million completed in October 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Neumora
Neumora has secured backing from 17 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, ARE and Citadel.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on life science companies
|
Locked | Locked | Locked | |
|
Early stage life sciences sectors focused VC firm investing in the US
|
Locked | Locked | Locked | |
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked |
Investor details for Neumora
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Neumora
Investment portfolio details for Neumora
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Neumora
Detailed financials for Neumora
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Neumora Comparisons
Peer comparison for Neumora
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Neumora
Neumora operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Biogen, Neurocrine, PTC Therapeutics and Biohaven Pharmaceutical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| Locked | Locked | Locked |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| Locked | Locked | Locked |
Developer of small molecule therapeutics for endocrine and CNS disorders
|
|
| Locked | Locked | Locked |
Small molecule drugs for rare diseases are developed.
|
|
| Locked | Locked | Locked |
Therapies for neurological and neuropsychiatric diseases are developed.
|
|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
Detailed competitors of Neumora
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Neumora
Complete news archive for Neumora
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Neumora
Neumora was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Neumora is headquartered in Watertown, United States.
Paul Berns is the current CEO of Neumora. They have also founded this company.
Neumora is a funded company, having raised a total of $612M across 2 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Neumora is 110.
Neumora was founded in 2020 and is headquartered in Watertown, United States. Precision medicines targeting neuropsychiatric and neurodegenerative disorders are developed through a data-driven neuroscience platform. Technologies such as Data Biopsy Signatures and Precision Phenotypes are utilized to enable targeted therapies for brain diseases. The pipeline encompasses NMRA-140 for depressive disorders, NMRA-511 for anxiety and sleep issues, and NMRA-094 for neurodegenerative conditions.
Neumora's top competitors include Jazz Pharmaceuticals, PTC Therapeutics and Neurocrine.
Neumora offers Precision Toolbox and Drug Pipeline Programs.
Yes, Neumora is publicly traded on NASDAQ under the ticker symbol NMRA.
Neumora has 17 investors. Key investors include Amgen, ARE, Citadel, Mubadala, and Arch Venture Partners.
The ticker symbol of Neumora is NMRA on NASDAQ.